Safety issues in the use of methylphenidate. An American perspective

Drug Safety

Volumn 17, Issue 3, 1997, Pages 143-148

  Rappley, Marsha D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ANEMIA; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; META ANALYSIS; PATIENT INFORMATION; PATIENT MONITORING; PRIORITY JOURNAL; RESTLESSNESS; SEDATION; SHORT SURVEY; SLEEP DISORDER; STOMACH PAIN; TREMOR; VERTIGO;

EID: 0030879506     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717030-00001     Document Type: Short Survey

References (48)

1. Barkley RA. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. New York: Guilford Press, 1990
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington. DC: American Psychiatric Association, 1994
3. Szatmari P, Offord DR, Boyle MH. Ontario child health study-prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry 1989; 30: 219-30
4. Taylor E. On the epidemiology of hyperactivity: attention deficit disorder, clinical and basic research. In: Sagrolden T, Archer T, editors. Hillsdale (NJ): Erlbaum, 1989: 31-52
5. Wender P. Attention deficit disorder in adults. New York: Oxford Press, 1994
6. Safer DJ, Zito JM, Fine EM. Increased methylphenidale usage for attention deficit disorder in the 1990s. Pediatrics 1996; 98 (6): 1084-8
7. Drug Enforcement Administration. ARCOS (Automation of Reports and Consolidated Orders Systems) Data Base 1981-1994. Washington, DC: US Department of Justice, 1996
8. Rappley MD, Gardiner JC, Jetton JR, et al. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995; 149: 675-9
9. Shaywitz SE, Shaywitz BA. Increased medication use in attention deficit hyperactivity disorder: regressive or appropriate? JAMA 1988; 260 (15): 2270-2
10. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35 (4): 409-32
11. Evans SW, Pelham WE. Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol 1991; 19: 537-52
12. Swanson JM, Cantwell DP, Lerner M, et al. Effects of stimulant medication on learning in children with ADHD. J Learn Disabil 1991; 4: 219-230, 255
13. Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990; 29 (5): 719-23
14. Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 1992; 15 (1): 69-85
15. Jacobvitz D, Sroufe LA, Stewart M, et al. Treatment of altentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990; 29: 677-88
16. Elia J. Drug treatment for hyperactive children: therapeuticguidelines. Drugs 1993; 46: 863-71
17. Kelly DP, Aylward GP. Development and behavior, older children and adolescents: attention deficits in school-aged children and adolescents. Pediatr Clin North Am 1992; 39 (3): 487-512
18. Klein RG, Manuzza S. Hyperactive boys almost grown up: III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry 1988; 45: 1131-4
19. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52: 444-55
20. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD und comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 589-96
21. Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30 (2): 241-5
22. Schleifer M, Weiss G, Cohen N, et al. Hyperactivity in preschoolers and the effect of methylphenidate. Am J Orthopsychiatry 1975; 45 (1): 38-50
23. Dunnick JK, Hailey JR. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 1995 Nov 30; 103 (2): 77-84
24. Gross-Tsur V, Manor O, Van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 1997; 130 (1): 6-9
25. Dulcan MK. Using psychostimulants to treat behavioral disorders of children and adolescents. J Child Adolesc Psychopharmacol 1990; 1 (1): 7-20
26. Wilens TE, Blederman J. Pediatric psychopharmacology: the stimulants. Psychiatr Clin North Am 1992; 15: 191-222
27. Huffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbard LE, editors. Goodman and Oilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill, 1996: 220
28. Carter HS, Watson WA. IV pentazocine/methylphenidate abuse: the clinical toxicity of another Ts and blues combination. J Toxicol Clin Toxicol 1994; 32 (5): 541-7
29. McBride MC. An individual double-blind crossover trial for assessing methylphenidate response in children with attention deficit disorder. J Pediatr 1989; 114 (5): 902-3
30. Ahmann PA, Waltonen SJ, Olson KA, et al. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993; 91 (6): 1101-6
31. Fine S, Johnston C. Drug and placebo side effects in methylphenidate-plaeebo trial for attention deficit hyperactivity disorder. Child Psychiatry Hum Dev 1993; 24 (1): 25-30
32. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyper- activity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86 (2): 184-92
33. Cantwell DP. Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35 (8): 978-87
34. Dyme IZ, Sahakian BJ, Golinko, et al. Perseveration induced by methylphenidate in children: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 269-73
35. Douglas VI, Barr RG, Desilets J, et al. Do high doses of stimulants impair flexible thinking in attention-deticit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 1995; 34 (7): 877-85
36. Johnston C, Pelham WE, Horz J. Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 1988; 27: 806-10
37. Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am 1996; 19 (3): 515-47
38. Wilens TE, Spencer T, Biederman J, et al. Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 1995; 34 (1): 110-2
39. Pataki CS, Carlson GA, Kelly KL, et al. Side effects of methylphenidate and desiprumine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 1993; 32 (5): 1065-72
40. Varley C, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 1997; 36 (3): 390-4
41. Swanson JR, Jones GR, Knisselt W, et al. Death of 2 subjects due to imipramine and desipramine metabolite accumulation during chronic therapy; a review of the literature and possible mechanisms. J Forensic Sci 1997; 42 (2): 335-9
42. Maloney M, Schwam J. Clonidine and sudden death. Pediatrics 1995; 96 (6): 1176-7
43. Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991; 151: 781-3
44. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30(5): 773-5
45. Drug Enforcement Administration. Methylphenidate: review document. Drug and Chemical Evaluation Section, Office of Diversion Control, US Department of Justice, 1995
46. CHADD Organization (Children and adults with attention deficit disorder) and the American Academy of Neurology. A petition to reclassify methylphenidate. Submitted to the Department of Justice, Oct 1994
47. United States Pharmacopeia 23, National Formulary 18. United States Pharmacopeil Convention, Inc. Rockville, MD, 1995: 1861-88
48. Johnson ISR, O'Malley P, Bechman J. National survey results on drug use for the monitoring the future study, 1975-1994: vol. 1. Secondary school students. Washington. DC: National Institute of Health, 1995: Rep. no. 95-4026